Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that CONNECT, a regional San Diego nonprofit organization, has selected Zogenix’s migrane treatment SUMAVEL(R) DosePro™ Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner.
The 2010 CONNECT MIP Awards recognize emerging technologies and cutting-edge products that drive San Diego’s innovation economy. SUMAVEL DosePro was awarded top ranking as the most innovative product for 2010 in the Life Sciences — Medical Products category.
SUMAVEL DosePro is a needle-free, quick response treatment for migraine attacks. The treatment is the first drug product approved by the U.S. Food and Drug Administration (FDA), which allows for the needle-free, subcutaneous delivery of medication.
“We are honored that CONNECT has recognized SUMAVEL DosePro, and by extension our proprietary DosePro delivery system, as a significant innovation. San Diego is a rich source of new and exciting technologies, and we are proud to be distinguished in the region as the most innovative medical product within the life sciences category,” Roger L. Hawley, CEO and director of Zogenix, stated in the press release.
Zogenix and its co-promotion partner Astellas Pharma US Inc. launched SUMAVEL DosePro in the United States in January 2010. Zogenix established a partnership with Desitin Arzneimittel GmbH to develop and commercialize SUMAVEL DosePro in the European Union, and the companies plan to launch SUMAVEL DosePro in Denmark in early 2011.
For additional information, visit www.zogenix.com